NanoViricides, Inc. Announces Additional Herpes Keratitis Study

Major research institution approves investigator-initiated study
WEST HAVEN, Conn.--(Business Wire)--
NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that the
Institutional Review Committee of a major research institute in New York has
approved an investigator-initiated in vivo study which will evaluate certain
topical nanoviricide eye drug candidates. This approved project is designed to
study the effect of different nanoviricide drug candidates on herpes simplex
virus (HSV) infection of the cornea. The Company will be providing the drug
candidates free of charge. The principal investigator is an Associate Professor
of Ophthalmology at the Albert Einstein School of Medicine. She has previously
conducted an in vivo study that resulted in the demonstration of a strong
clinical effect of certain nanoviricide drug candidates against adenovirus
induced keratoconjunctivitis in rabbit eyes.

There are about 50,000 cases of HSV infection of the cornea in the US alone each
year. It is generally caused by HSV Type I. Many of these cases lead to
substantial scarring of the cornea and significantly reduced vision, which may
necessitate corneal transplantation. Current treatment requires intensive
monitoring and specialized procedures conducted by an ophthalmologist, often
lasting several weeks to months. If the simple eye drops of an anti-herpes
nanoviricide candidate produce rapid clinical resolution of the viral infection,
as was found previously with adenoviral infection of the eye, such nanoviricide
treatment could lead to a significant reduction in the direct health care costs
pertaining to treating this disease. In addition, such an effective treatment
could lead to a significant reduction in the number of corneal transplants
required to treat this number one cause of corneal blindness in the developed
world.

About NanoViricides:

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that
is creating special purpose nanomaterials for viral therapy. The Company's novel
nanoviricide class of drug candidates are designed to specifically attack
enveloped virus particles and to dismantle them. The Company is developing drugs
against a number of viral diseases including H5N1 bird flu, seasonal Influenza,
HIV, EKC, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.

This press release contains forward-looking statements that reflect the
Company's current expectation regarding future events. Actual events could
differ materially and substantially from those projected herein and depend on a
number of factors. Certain statements in this release, and other written or oral
statements made by NanoViricides, Inc. are "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. You should not place undue reliance on
forward-looking statements since they involve known and unknown risks,
uncertainties and other factors which are, in some cases, beyond the Company's
control and which could, and likely will, materially affect actual results,
levels of activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking statements for any
reason, or to update the reasons actual results could differ materially from
those anticipated in these forward-looking statements, even if new information
becomes available in the future. Important factors that could cause actual
results to differ materially from the company's expectations include, but are
not limited to, those factors that are disclosed under the heading "Risk
Factors" and elsewhere in documents filed by the company from time to time with
the United States Securities and Exchange Commission and other regulatory
authorities. Although it is not possible to predict or identify all such
factors, they may include the following: demonstration and proof of principle in
pre-clinical trials that a nanoviricide is safe and effective; successful
development of our product candidates; our ability to seek and obtain regulatory
approvals, including with respect to the indications we are seeking; the
successful commercialization of our product candidates; and market acceptance of
our products.

NanoViricides, Inc.
Amanda Schuon, 310-550-7200
info@nanoviricides.com

Copyright Business Wire 2009